{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:10:24Z","timestamp":1792069824597,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1124\/dmd.118.085977","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T00:11:51Z","timestamp":1555459911000},"page":"690-698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects"],"prefix":"10.1016","volume":"47","author":[{"given":"Philip","family":"Krieter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Nora","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwe","family":"Gyaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Skolnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.085977_bib1","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1021\/acs.molpharmaceut.5b00103","article-title":"Microarray determination of the expression of drug transporters in humans and animal species used for the investigation of nasal absorption","volume":"12","author":"Al-Ghabeish","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.118.085977_bib2","unstructured":"Brown DC, Montgomery J, and Gertz B (2014) inventors, 3B Pharmaceuticals, Inc., assignee. Intranasal naltrexone. U.S. patent 2014\/0249172 A1. 2014 Sep 4."},{"key":"10.1124\/dmd.118.085977_bib3","first-page":"e96","article-title":"Opioid overdose and naloxone delivery devices in the community setting","volume":"8","author":"Carpenter","year":"2016","journal-title":"Am J Pharm Benefits"},{"key":"10.1124\/dmd.118.085977_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2005.08.008","article-title":"[3H]Alvimopan binding to the \u03bc opioid receptor: comparative binding kinetics of opioid antagonists","volume":"520","author":"Cassel","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.118.085977_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/dmd.118.085977_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: physicochemical and therapeutic aspects","volume":"337","author":"Costantino","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1124\/dmd.118.085977_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40122-015-0035-9","article-title":"Comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery","volume":"4","author":"Edwards","year":"2015","journal-title":"Pain Ther"},{"key":"10.1124\/dmd.118.085977_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2273.1999.00223.x","article-title":"Nasal pH measurement: a reliable and repeatable parameter","volume":"24","author":"England","year":"1999","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"10.1124\/dmd.118.085977_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(24)39041-X","article-title":"Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier","volume":"294","author":"Gao","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.118.085977_bib10","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/jps.23901","article-title":"Establishment of optimized MDCK cell lines for reliable efflux transport studies","volume":"103","author":"Gartzke","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.118.085977_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.118.085977_bib12","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids","volume":"134","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.118.085977_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1165\/rcmb.2006-0230OC","article-title":"Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway","volume":"36","author":"Horvath","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1124\/dmd.118.085977_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.118.085977_bib15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1472-8206.2009.00724.x","article-title":"P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone","volume":"23","author":"Kanaan","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/dmd.118.085977_bib16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/dmd.112.050054","article-title":"Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells)","volume":"41","author":"Kazmi","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.085977_bib17","first-page":"1726","article-title":"Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system","volume":"38","author":"Kim","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.118.085977_bib18","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/10903127.2017.1335818","article-title":"Incidence of naloxone redosing in the age of the new opioid epidemic","volume":"21","author":"Klebacher","year":"2017","journal-title":"Prehosp Emerg Care"},{"key":"10.1124\/dmd.118.085977_bib19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1124\/jpet.105.094409","article-title":"Differential in vivo potencies of naltrexone and 6\u03b2-naltrexol in the monkey","volume":"316","author":"Ko","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.118.085977_bib20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jcph.759","article-title":"Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose","volume":"56","author":"Krieter","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.118.085977_bib21","doi-asserted-by":"crossref","unstructured":"Krieter P, Gyaw S, Chiang CN, Crystal R, Skolnick P (2019) Enhanced intranasal absorption of naltrexone by dodecyl maltopyranoside: implications for the treatment of opioid overdose. J Clin Pharmacol DOI: 10.1002\/jcph.1384 [published ahead of print].","DOI":"10.1002\/jcph.1384"},{"key":"10.1124\/dmd.118.085977_bib22","first-page":"1207","article-title":"Duration of occupancy of opiate receptors by naltrexone","volume":"29","author":"Lee","year":"1988","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.118.085977_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.annemergmed.2018.05.010","article-title":"Narcan or Nar-can\u2019t: tips and tricks to safely reversing opioid toxicity","volume":"72","author":"Li","year":"2018","journal-title":"Ann Emerg Med"},{"key":"10.1124\/dmd.118.085977_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s13346-012-0069-z","article-title":"High efficiency intranasal drug delivery using Intravail\u00ae alkylsaccharide absorption enhancers","volume":"3","author":"Maggio","year":"2013","journal-title":"Drug Deliv Transl Res"},{"key":"10.1124\/dmd.118.085977_bib25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.102.039255","article-title":"Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs","volume":"303","author":"Mahar Doan","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.118.085977_bib26","first-page":"15","article-title":"Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration","volume":"45","author":"Meyer","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/dmd.118.085977_bib27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/mp.2011.29","article-title":"Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans","volume":"16","author":"Rabiner","year":"2011","journal-title":"Mol Psychiatry"},{"key":"10.1124\/dmd.118.085977_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/pmt-2017-0060","article-title":"Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review","volume":"8","author":"Ryan","year":"2018","journal-title":"Pain Manag"},{"key":"10.1124\/dmd.118.085977_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.2042-7158.1994.tb03817.x","article-title":"Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the dissociation of the drug","volume":"46","author":"Sakane","year":"1994","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.118.085977_bib30","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1248\/bpb.17.1135","article-title":"Nasal absorption of zidovudine and its transport to cerebrospinal fluid in rats","volume":"17","author":"Seki","year":"1994","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.118.085977_bib31","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/jcph.552","article-title":"Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): a randomized, controlled abuse-potential study in nondependent recreational opioid users","volume":"55","author":"Setnik","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.118.085977_bib32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4155\/tde.13.10","article-title":"Organic cation transporters in human nasal primary culture: expression and functional activity","volume":"4","author":"Shao","year":"2013","journal-title":"Ther Deliv"},{"key":"10.1124\/dmd.118.085977_bib33","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/aas.12898","article-title":"Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers","volume":"61","author":"Vanky","year":"2017","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1124\/dmd.118.085977_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13346-012-0092-0","article-title":"A response to the opioid overdose epidemic: naloxone nasal spray","volume":"3","author":"Wermeling","year":"2013","journal-title":"Drug Deliv Transl Res"},{"key":"10.1124\/dmd.118.085977_bib35","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/j.1526-4637.2011.01279.x","article-title":"6\u03b2-Naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study","volume":"12","author":"Yancey-Wrona","year":"2011","journal-title":"Pain Med"},{"key":"10.1124\/dmd.118.085977_bib36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1081\/DDC-100102181","article-title":"Comparative bioavailability study of a generic naltrexone tablet preparation","volume":"25","author":"Yuen","year":"1999","journal-title":"Drug Dev Ind Pharm"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624077997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624077997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.085977","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:23:26Z","timestamp":1739957006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624077997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0090955624077997"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.085977","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.085977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"U.S. Government work not protected by U.S. copyright","name":"copyright","label":"Copyright"}]}}